Dexcom Inc
DXCM
Market Cap$51.77B
Close$
Earnings Call Q4 2023
February 8, 2024 - AI Summary
Dexcom reported strong financial results for the fourth quarter and fiscal year 2023, with total revenue growing by 27% on a reported basis and 26% on an organic basis.
The company added over 600,000 new customers in 2023, ending the year with approximately 2.3 million customers globally.
Dexcom's G7 CGM system has been well-received in the market, driving changes in prescribing patterns and attracting a larger cohort of clinicians to the ecosystem.
Exclusive for Stockcircle Pro members
Sign up
$29.52
78.6% downside
Current Fair Value
78.6% downsideOvervalued by 78.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $51.77 Billion |
|---|---|
| Enterprise Value | $51.54 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $1.27 |
| Beta | 0.88 |
| Outstanding Shares | 385,515,421 |
| Avg 30 Day Volume | 2,369,342 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 95.61 |
|---|---|
| PEG | 53.36 |
| Price to Sales | 15.32 |
| Price to Book Ratio | 27.57 |
| Enterprise Value to Revenue | 14.23 |
| Enterprise Value to EBIT | 85.96 |
| Enterprise Value to Net Income | 95 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 1.21 |
Revenue Sources
No data
ESG Score
No data
About Dexcom Inc
CEO: Kevin Sayer